Home Cart Sign in  
Chemical Structure| 566939-85-3 Chemical Structure| 566939-85-3

Structure of Orteronel
CAS No.: 566939-85-3

Chemical Structure| 566939-85-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Orteronel is a highly selective inhibitor of human 17,20-lyase with IC50 of 38 nM, and exhibits > 1000-fold selectivity over other CYPs such as 11-hydroxylase and CYP3A4.

Synonyms: TAK-700

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Orteronel

CAS No. :566939-85-3
Formula : C18H17N3O2
M.W : 307.35
SMILES Code : O=C(C1=CC=C2C=C([C@@]3(O)CCN4C=NC=C43)C=CC2=C1)NC
Synonyms :
TAK-700
MDL No. :MFCD20528078
InChI Key :OZPFIJIOIVJZMN-SFHVURJKSA-N
Pubchem ID :9796590

Safety of Orteronel

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01046916 Prostate Cancer PHASE2 COMPLETED 2025-03-13 University of Michigan Compreh... More >>ensive Cancer Center, Ann Arbor, Michigan, 48109, United States|Oregon Health and Sciences University, Portland, Oregon, 97239, United States|University of Wisconsin Hospitals and Clinics, Madison, Wisconsin, 53705, United States Less <<
NCT01990209 Metastatic Breast Cancer PHASE2 COMPLETED 2021-05-01 Yale School of Medicine, New H... More >>aven, Connecticut, 06520, United States|Northeast Georgia Medical Center, Gainesville, Georgia, 30501, United States|Hope Cancer Center, Terre Haute, Indiana, 47802, United States|Baptist Hospital East, Louisville, Kentucky, 40207, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, 20817, United States|Cancer Research Consortium of West Michigan, Grand Rapids, Michigan, 49503, United States|Cancer Centers of SW Oklahoma, Lawton, Oklahoma, 73505, United States|Tennessee Oncology PLLC, Chattanooga, Tennessee, 37404, United States|Tennessee Oncology PLLC, Nashville, Tennessee, 37203, United States|Center for Cancer and Blood Disorders, Fort Worth, Texas, 76104, United States Less <<
NCT00569153 Prostatic Neoplasms PHASE1|PHASE2 COMPLETED 2025-02-13 USC Westside Prostate Cancer C... More >>enter, Beverly Hills, California, United States|University of Southern California, Los Angeles, California, 90048, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|South Florida Medical Research, Aventura, Florida, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|Northwestern University Medical Center, Chicago, Illinois, 60611, United States|University of Chicago, Chicago, Illinois, 60637, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|University of Chicago Pharmacy, Chicago, Illinois, United States|Evanston Hospital, Evanston, Illinois, United States|Kellogg Pharmacy - Evanston Hospital, Evanston, Illinois, United States|NorthShore University HealthSystem, Evanston, Illinois, United States|Kellogg Cancer Care Center, Glenview, Illinois, United States|Hematology/Oncology Associates of Central New York, East Syracuse, New York, United States|Gabrail Cancer Center, Canton, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, 44195, United States|Taussig Cancer Institute, Cleveland, Ohio, United States|Tennessee Oncology, Nashville, Tennessee, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.25mL

0.65mL

0.33mL

16.27mL

3.25mL

1.63mL

32.54mL

6.51mL

3.25mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories